About Sally-Anne Tsangarides

Energetic leader with track record of rapidly building and motivating collaborative multi-disciplinary teams to launch and commercialise medicines in northern European markets for orphan products in rare genetic diseases. Currently GM for start-up and launch of Zolgensma, gene replacement therapy in spinal muscular atrophy in UK. Previously led launch of first treatment for an ultra-rare neuro-ophthalmological disease in UK, Ireland and Nordics in start-up phase together with pre-launch in Duchenne muscular dystrophy, including Early Access to Medicines Scheme in UK, patient group and clinical expert engagement and reimbursement agency engagement. Confident leading reimbursement/HTA processes in northern European markets with track record of success. Previously led launches of enzyme replacement therapies for ultra-rare metabolic disorders in children, including two concurrent NICE HST appraisals. Engaged and creative market partner in global strategic brand planning. Resilient leader of organisational and cultural change.